Business Context and Reporting Period
This Form 8-K Current Report is filed by Cartesian Therapeutics, Inc. (RNAC) on October 15, 2025. The report discloses a material corporate governance event involving the termination of a senior executive officer.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on executive compensation and employment termination details.
Material Changes
- Executive Departure: The Company eliminated the position of Chief Scientific Officer (CSO) and terminated Christopher Jewell, Ph.D., without cause, effective November 14, 2025.
- Separation Agreement: On October 20, 2025, the Company and Dr. Jewell executed a Separation Agreement and Release.
- Severance Terms: Dr. Jewell is entitled to 12 months of salary and a pro-rated bonus under the terms of his March 26, 2024, employment agreement.
- Legal Release: In exchange for severance, Dr. Jewell agreed to release the Company from claims arising up to November 14, 2025.
Guidance, Outlook, and Risks
The filing contains no financial guidance, operational outlook, or discussion of general business risks. The primary contingency noted is the execution of the Separation Agreement, a copy of which is expected to be filed in the Company's 2025 Form 10-K.
Investor Verification Checklist
- Verify the impact of the CSO departure on the Company's clinical development pipeline and scientific strategy.
- Review the full Separation Agreement (Exhibit 10.14 to the 2024 10-K and future 2025 10-K) for specific non-compete or non-solicit clauses.
- Confirm the total cash outflow associated with the 12-month salary and pro-rated bonus in upcoming quarterly reports.
- Monitor for any interim appointment of a new Chief Scientific Officer or restructuring of the scientific leadership team.